About Huihui Ye
There is no curative treatment available for high-risk, primary prostate cancer patients. Most of these tumors will initially respond to androgen deprivation therapy (ADT) but inevitably recur as a lethal form of castrate-resistant prostate cancer (CRPC).
Dr. Huihui Ye will identify molecular mechanisms and biomarkers of treatment resistance in patients from a phase 2 neoadjuvant intense ADT clinical trial – a combinatorial regimen of conventional ADT (Lupron) plus abiraterone acetate (AA).
Resistance mechanisms that will be explored include altered activation of the androgen receptor (AR), the primary prostate cancer oncogene and target of these therapies, and activation of a novel oncogene, Sox9.
If successful, this study will identify mechanisms of resistance to intense ADT and will help to develop combination therapies to increase response and cure rates.
What this means for patients: Many patients diagnosed with primary high risk prostate cancer who are treated with androgen deprivation therapy (ADT) will eventually develop recurrent, lethal, ADT-resistant disease. This study will identify mechanisms and biomarkers of ADT resistance to inform optimal treatment of patients with potentially lethal disease.
2014 Stewart Rahr-PCF Young Investigator
Huihui Ye, MD
Harvard Medical School: Beth Israel Deaconess Medical Center
Steven Balk, MD, PhD
Investigation of Molecular Mechanisms and Biomarkers of Treatment Resistance in a Randomized, Phase 2 Neoadjuvant Intense Androgen Deprivation Trial in Patients with Localized, Intermediate to High Risk Prostate Cancer